Multiple Phase III trials have shown positive results, and on 2022, both of the FDA and the European Medical Agency (EMA) approved Opdualag (a fixed-dose combination of the anti-LAG-3-blocking mAb relatlimab and the anti-PD-1-blocking mAb nivolumab) for the treatment of adults and children 12 years of age or older with unresectable or metastatic melanoma [7]. Here, LAG3 is linked to metastatic melanoma.